Eli Lilly & Co said that its drug Jardiance, along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes.
Jardiance, although not approved for type-1 diabetes, is approved for use in adults with type 2 diabetes, a more prevalent form of the disease. Jardiance, along with two other diabetes medicines, raked in sales of $151 million in the first quarter for the drugmaker.
Type 1 diabetes currently affects 1.3 million adults in the United States and about 30 million adults worldwide, the companies said.
The full results from the late-stage program would be presented at the European Association for the Study of Diabetes Annual Meeting in October.